-+ 0.00%
-+ 0.00%
-+ 0.00%

Bicara Therapeutics shareholders re-elect Bowden, Ng as Class II directors

PUBT·06/10/2026 20:06:25
Listen to the news
Bicara Therapeutics shareholders re-elect Bowden, Ng as Class II directors
  • Bicara Therapeutics held its annual shareholder meeting on June 9, 2026.
  • Shareholders backed the selection of Christopher Bowden, M.D. and Carolyn Ng, Ph.D. to serve as directors.
  • Investors also ratified KPMG as independent registered public accounting firm for the fiscal year ending Dec. 31, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-042176), on June 10, 2026, and is solely responsible for the information contained therein.